These Analysts Slash Their Forecasts On Edwards Lifesciences Following Q2 Results
Portfolio Pulse from Avi Kapoor
Edwards Lifesciences Corporation (NYSE:EW) reported worse-than-expected Q2 sales and issued lower-than-expected Q3 guidance. Despite beating earnings estimates, the stock fell 28.4% due to the sales miss and downgraded price targets from multiple analysts.
July 25, 2024 | 5:36 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Edwards Lifesciences reported Q2 sales below expectations and issued weak Q3 guidance. Despite beating earnings estimates, the stock fell 28.4%. Multiple analysts downgraded their price targets.
The company's Q2 sales miss and weak Q3 guidance have led to a significant stock price drop. Multiple analysts have downgraded their price targets, indicating a negative short-term outlook.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100